Further, with the development of targeted therapies, the outcomes for patients diagnosed with hormone receptor-positive (HR+) and/or human epidermal growth factor receptor 2-positive (HER2+) BC has continued to improve. This evidence concerns the gene ERBB2 and breast cancer.